Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00375128
Other study ID # VAC027.2
Secondary ID EudraCT number:
Status Completed
Phase Phase 1/Phase 2
First received September 10, 2006
Last updated October 18, 2007
Start date September 2006
Est. completion date April 2007

Study information

Verified date October 2007
Source European Malaria Vaccine Initiative
Contact n/a
Is FDA regulated No
Health authority United Kingdom: Medicines and Healthcare Products Regulatory Agency
Study type Interventional

Clinical Trial Summary

This study examines the ability of two new malaria vaccines (FP9-PP and MVA-PP) to prevent the development of malaria infection after controlled exposure to the parasite. Volunteers for this trial will have received these vaccines in the preceding trial VAC027.1.


Description:

Malaria infection kills over 2 million people each year. It is a major problem for those who live in endemic areas and for travellers. There is clearly a great need for a safe effective malaria vaccine.

The purpose of this study is to test the clinical efficacy of two candidate malaria vaccines (FP9-PP and MVA-PP). These live viral vector vaccines were administered in a 'prime boost' regime in the preceding trial VAC027.1.

Volunteers will now be exposed to 5 infective bites from mosquitoes carrying P. falciparum malaria.

This trial will:

1. Measure efficacy as the time in hours from malaria exposure to blood film positive for malaria parasites

2. Examine immunogenicity before and after malaria infection

3. Measure longer term vaccine efficacy by re-challenging any protected volunteers 6 - 12 months later


Recruitment information / eligibility

Status Completed
Enrollment 26
Est. completion date April 2007
Est. primary completion date
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 18 Years to 50 Years
Eligibility Inclusion Criteria:

- Healthy non-pregnant adults aged 18 to 50 years

- The vaccinated group will be subjects who have received the vaccine regime described for group 6 or 7 in VAC027.1

- Resident in or near Oxford, UK for the duration of the challenge study

- For females only, willingness to practice effective contraception during the challenge study.

- Agreement to refrain from blood donation during the course of the study

- Written informed consent

- Willingness to allow the investigators to access hospital and General Practitioner medical notes

- Willingness to undergo an HIV test

Exclusion Criteria:

- Any deviation from the protocol-defined normal range in biochemistry or haematology blood tests or in urine analysis

- Prior receipt of an investigational malaria vaccine (unless administered in VAC027.1)

- Use of any investigational or non-registered drug, live vaccine or medical device other than the study vaccine within 30 days preceding dosing of study vaccine, or planned use during the study period

- Administration of chronic immunosuppressive drugs or other immune modifying drugs within six months of vaccination

- History of malaria chemoprophylaxis with chloroquine within 5 months prior to the planned challenge, with Lariam within 6 weeks prior to the challenge, and Riamet within 2 weeks prior to the challenge

- Any history of malaria

- Travel to a malaria endemic country within the previous 3 months prior to the planned challenge

- Planned travel to malarious areas during the study period

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection and asplenia

- Evidence of cardiovascular disease

- History of cancer (except basal cell carcinoma of the skin and cervical carcinoma in situ)

- History of haemoglobinopathies

- History of diabetes mellitus

- Chronic or active neurological disease requiring ongoing specialist supervision

- Chronic gastrointestinal disease requiring ongoing specialist supervision

- History of > 2 hospitalisations for invasive bacterial infections (pneumonia, meningitis)

- Suspected or known current alcohol abuse as defined by an alcohol intake of greater than 42 units every week

- Seropositive for hepatitis B surface antigen (HBsAg)

- Seropositive for hepatitis C virus (antibodies to HCV)

- Hepatomegaly, right upper quadrant abdominal pain or tenderness

- Evidence of serious psychiatric condition

- Any other on-going chronic illness requiring hospital specialist supervision

- Acute disease at the time of enrolment

- Administration of immunoglobulins and/or any blood products within the three months preceding the planned administration of the vaccine candidate

- Pregnant or lactating female

- Female who is willing or intends to become pregnant during the study

- History of severe reactions or allergy to mosquito bites

- PI assessment of lack of willingness to participate and comply with all requirements of the protocol

- History or clinical evidence of intravenous drug abuse

- Any other finding which in the opinion of the investigator would significantly increase the risk of having an adverse outcome from participating in this protocol

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention


Related Conditions & MeSH terms


Intervention

Biological:
FP9-PP (FP9 polyprotein)

MVA-PP (Modified Virus Ankara polyprotein)


Locations

Country Name City State
United Kingdom Imperial College, University of London London
United Kingdom Centre for Clinical Vaccinology & Tropical Medicine, University of Oxford Oxford

Sponsors (4)

Lead Sponsor Collaborator
European Malaria Vaccine Initiative University of Oxford, Walter Reed Army Institute of Research (WRAIR), Wellcome Trust

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy (time in hours to parasitaemia)
Secondary Immunogenicity
See also
  Status Clinical Trial Phase
Completed NCT04601714 - Baseline Cohort Malaria Morbidity Study
Withdrawn NCT04020653 - A Study to Assess the Safety and Efficacy of 5-aminolevulinic Acid Hydrochloride (5-ALA HCl) and Sodium Ferrous Citrate (SFC) Added on Artemisinin-based Combination Therapy (ACT) in Adult Patients With Uncomplicated Malaria Phase 2
Terminated NCT04368910 - Safety and Efficacy of Pyronaridine Artesunate Vs Chloroquine in Children and Adult Patients With Acute Vivax Malaria Phase 3
Completed NCT03641339 - Defining Skin Immunity of a Bite of Key Insect Vectors in Humans N/A
Completed NCT02544048 - Markers of T Cell Suppression: Antimalarial Treatment and Vaccine Responses in Healthy Malian Adults
Completed NCT00527163 - Role of Nitric Oxide in Malaria
Not yet recruiting NCT05934318 - L-ArGinine to pRevent advErse prEgnancy Outcomes (AGREE) N/A
Active, not recruiting NCT04704674 - Community Dynamics of Malaria Transmission in Humans and Mosquitoes in Fleh-la and Marshansue, Salala District, Bong County, Liberia
Completed NCT03276962 - Efficacy, Safety and Immunogenicity Study of GSK Biologicals' Candidate Malaria Vaccine (SB257049) Evaluating Schedules With or Without Fractional Doses, Early Dose 4 and Yearly Doses, in Children 5-17 Months of Age Phase 2
Completed NCT04966871 - Safety, Tolerability and Efficacy of PfSPZ Vaccine Against Heterologous CHMI in US Malaria naïve Adults Phase 1
Completed NCT00289185 - Study of Safety, Immunogenicity and Efficacy of a Candidate Malaria Vaccine in Tanzanian Infants Phase 2
Recruiting NCT03937817 - Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants
Active, not recruiting NCT06153862 - Africa Ready Malaria Screening N/A
Completed NCT04545905 - Antenatal Care as a Platform for Malaria Surveillance: Utilizing Community Prevalence Measures From the New Nets Project to Validate ANC Surveillance of Malaria in Burkina Faso
Recruiting NCT06278181 - Diabetes, Metabolic Syndrome and Risk of Malaria in Cameroon
Completed NCT02793622 - Prevention of Malaria in HIV-uninfected Pregnant Women and Infants Phase 3
Withdrawn NCT02793414 - Diagnostic Utility of Volatile Organic Compounds in Human Breath for Acute Clinical Malaria in Ethiopia
Withdrawn NCT02793388 - A Trial on Supervised Primaquine Use in Ethiopia Phase 4
Completed NCT02909712 - Cardiac Safety of Dihydroartemisinin-Piperaquine Amongst Pregnant Women in Tanzania Phase 2
Completed NCT02605720 - Cardiac Safety of Repeated Doses of Dihydroartemisinin-Piperaquine for the Use in Mass Treatment Campaigns Phase 3